Bionano Genomics (BNGO) Current Assets (2017 - 2026)

Bionano Genomics has disclosed Current Assets across 10 years of filings, most recently posting $39.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $39.0 million, down 13.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.0 million (down 13.25% YoY), and the FY2025 annual result was $45.4 million, up 14.93% from the prior year.
• Current Assets came in at $39.0 million for Q1 2026 at Bionano Genomics, down from $45.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $242.4 million in Q1 2022 to a low of $39.0 million in Q1 2026.
• The 5-year median for Current Assets is $85.6 million (2024), against an average of $105.7 million.
• Across the five-year window, Current Assets slumped 71.82% in 2024 and advanced 14.93% in 2025, its largest moves.
• Bionano Genomics' Current Assets stood at $157.3 million in 2022, then decreased by 10.92% to $140.1 million in 2023, then plunged by 71.82% to $39.5 million in 2024, then climbed by 14.93% to $45.4 million in 2025, then fell by 14.13% to $39.0 million in 2026.
• The last three Current Assets figures came in at $39.0 million (Q1 2026), $45.4 million (Q4 2025), and $48.8 million (Q3 2025), per Business Quant data.